|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | SF_6断路器的热开断性能的数值预测(英文)显示文摘The design technology for HV SF6 gas circuit breakers is very demanding.A numerical method for prediction of the thermal interruption capability of SF6 gas circuit breakers is established based on the two-dimensional magneto-hydrodynamic(MHD) model and a commercial CFD(computational fluid dynamics) software,FLUENT.Nozzle ablation effect is considered by introducing an independent mass conservation equation for the ablated material to the overall conservation equations of mass,momentum,and energy.The ohmic heating and the radiation of the electric arc are considered in the model by adding relevant source terms.To predict the thermal interruption capability,the arc conductance 200 ns before current zero is used as an indicator.The CFD model is applied for the high current arcing phase,and Mayr arc model is used near the current zero period.The arc conductance at 200 ns before current zero(G200) for various arcing periods are computed by the present method.It shows that there exist a limit of the G200.For those whose arcing periods are within the arcing window,the related G200 are below the limit,therefore result a successful current interruption,and vice versa.The validation of the developed computer simulation tool is therefore verified.The numerical prediction by the simulation tool is verified by the direct interrupting test of 550 kV gas circuit breaker(GCB).The developed computer simulation tool was applied in the design of a 550 kV GCB.Significant benefits have been achieved in terms of both the cost saving and shorten of the development cycle. | MU Jingwei GUO Jin DENG Xiang'e | 2013 | 高电压技术2013，39，4： | 6 |
| 2 | Addition of statins to the standard treatment in patients with cirrhosis:Safety and efficacy显示文摘This review summarizes the safety and efficacy of statins in patients with cirrhosis.Due to concerns about the safety of statins in patients with impaired liver function,they have recently been investigated as a potential treatment option in cirrhosis.The most clinically significant adverse event is statin-related myopathy,and this may be related to the high serum statin concentrations in the setting of severely impaired liver function.Rhabdomyolysis is the most serious and potentially life-threatening manifestation.It has recently been demonstrated that the recommended dose of simvastatin in patients with decompensated cirrhosis would be 20 mg/d because higher values,such as 40 mg/d,are associated with many adverse events,especially muscle injury.Likewise,simvastatin should not be administered to patients with Model for End-stage Liver Disease score>12 and/or Child-Pugh class C because of the high risk of severe muscle injury.Due to the pleiotropic effects,the focus on statins has shifted from being considered harmful to something useful.Through these effects,statins could prevent liver-related morbidity and mortality in cirrhotic patients.Observational studies in large populations of patients with cirrhosis have shown that treatment with statins to decrease high cholesterol levels was associated with a reduced risk of hepatic decompensation,hepatocellular carcinoma development and death.The few randomized controlled trials in patients with cirrhosis and portal hypertension showed that statins lower portal pressure,quite likely through a reduction in hepatic resistance.Another large randomized controlled trial in patients with variceal bleeding showed that simvastatin in addition to standard of care did not prevent rebleeding but improved survival rate.Despite these encouraging outcomes,the quality of the evidence regarding the use of statins is low or very low due to the observational characteristics of most of the studies involved.Therefore,it is advisable to perform further randomized controlled trials on a large series of patients with hard clinical endpoints,using different statin types and varying doses.The objectives would be to prevent liver-related morbidity and mortality rather than treating cirrhosis complications to take additional information that makes it possible to add statins to the standard of care of these patients. | Alberto E Muñoz Florencia D Pollarsky Mónica Marino Mariano Cartier Horacio Vázquez Pablo Salgado Gustavo Romero | 2021 | World Journal of Gastroenterology2021，27，28： | 4 |
| 3 | Efficacy and Safety of Yanggan Jian in Hepatitis B Virusrelated Decompensated Cirrhosis:A Randomized,Doubleblind,Controlled Trial显示文摘Background and Aims:The aim was to evaluate the efficacy and safety of Yanggan Jian(YGJ)in HBV-infected patients with decompensated cirrhosis.Methods:This randomized,double-blind controlled trial enrolled 160 patients with HBV-related decompensated cirrhosis who were already receiving or about to start antiviral therapy.Patients were randomly assigned to receive YGJ or placebo for 24 weeks,and were followed-up to 36 weeks.The primary outcome was the proportion of patients with a≥2 point reduction in Child-Turcotte-Pugh(CTP)score from baseline at week 24.Secondary outcomes were CTP class and score,serum liver function indices,mortality,incidence of hepatocellular carcinoma and variceal bleeding.Results:The proportion of patients with a CTP score reduction≥2 was significantly greater in the YGJ than in the placebo group(p=0.009);the percentage of patients with CTP class C was significantly less than that in the placebo group(p<0.05),and the YGJ group had a significantly greater mean change from baseline in CTP score at week 24(p=0.034).The improvement in measured values and change from baseline of prothrombin time,serum albumin,platelets,cholinesterase,international normalized ratio,and activated partial thromboplastin time were significantly better with YGJ than with placebo.Between-group differences in cumulative rates of variceal bleeding,hepatocellular carcinoma,death,or the frequency of any adverse event(AE),AEs related to treatment,or discontinuation because of AEs were not significant.Conclusions:YGJ significantly improved CTP scores and hepatic synthetic and reserve function in patients with HBV-related decompensated cirrhosis,and was safe and well tolerated. | Long Chen Chaoqun Zhao Weili Yao Wei Liu Hua Zhang Yongping Mu Hong Cai Dongying Xue Chengbao Wang Wan’e Wang Yuehong Lin Jiamei Chen Ping Liu | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 3 |
| 4 | Production and activity of matrix metalloproteinases during liver fibrosis progression of chronic hepatitis C patients显示文摘BACKGROUND Matrix metalloproteinases(MMPs)participate in the degradation of extracellular matrix compounds,maintaining the homeostasis between fibrogenesis and fibrolytic processes in the liver.However,there are few studies on the regulation of liver MMPs in fibrosis progression in humans.AIM To assess the production activity and regulation of matrix metalloproteinases in liver fibrosis stages in chronic hepatitis C(CHC).METHODS A prospective,cross-sectional,multicenter study was conducted.CHC patients were categorized in fibrosis grades through FibroTest®and/or FibroScan®.Serum MMP-2,-7,and-9 were determined by western blot and multiplex suspension array assays.Differences were validated by the Kruskal-Wallis and Mann-Whitney U tests.The Spearman correlation coefficient and area under the receiver operating characteristic curve were calculated.Collagenolytic and gelatinase activity was determined through the Azocoll substrate and zymogram test,whereas tissue inhibitor of metalloproteinase-1 production was determined by dot blot assays.RESULTS Serum concentrations of the MMPs evaluated were higher in CHC patients than in healthy subjects.MMP-7 distinguished early and advanced stages,with a correlation of 0.32(P<0.001),and the area under the receiver operating characteristic displayed moderate sensitivity and specificity for MMP-7 in F4(area under the receiver operating characteristic,0.705;95%confidence interval:0.605-0.805;P<0.001).Collagenolytic activity was detected at F0 and F1,whereas gelatinase activity was not detected at any fibrosis stage.Tissue inhibitor of metalloproteinase-1 determination showed upregulation in F0 and F1 but downregulation in F2(P<0.001).CONCLUSION High concentrations of inactive MMPs were present in the serum of CHC patients,reflecting the impossibility to restrain liver fibrosis progression.MMPs could be good diagnostic candidates and therapeutic targets for improving novel strategies to reverse liver fibrosis in CHC. | Moises Martinez-Castillo Abigail Hernandez-Barragan Ivonne Flores-Vasconcelos Marina Galicia-Moreno Dorothy Rosique-Oramas Jose Luis Perez-Hernandez Fatima Higuera-De la Tijera Eduardo E Montalvo-Jave Aldo Torre-Delgadillo Paula Cordero-Perez Linda Muñoz-Espinosa David Kershenobich Gabriela Gutierrez-Reyes | 2021 | World Journal of Hepatology2021，13，2： | 2 |
| 5 | Scent of dying cells:the role of attraction signals in the clearance of apoptotic cells and its immunological consequences显示文摘 | MU(N)OZ L E PETER C HERRMANN M | 2010 | Autoimmun Rev2010，9，6： | 1 |
| 6 | Recent advances in kidney cancer and metastatic disease显示文摘 | Kirkali Z Tuzel E Mungan MU | 2001 | BJU Int2001，88，8： | 1 |
| 7 | Central venous 02 saturation and venous-to-arterial CO2 difference as complementary tools for goal-directed therapy during high-risk surgery 显示文摘 | Futier E Robin El Jabaudon Mu | 2010 | Crit Care2010，14，193： | 1 |
| 8 | A microRNA polycistron as a potential human oncogene显示文摘 | He L Thomson JM Hemann MT Hernando-Monge E Mu D Goodson S Powers S Cordon-Cardo C.Lowe SW Hannon GJ | | 0，，： | 1 |
| 9 | Hip involve- ment in ankylosing spondylitis: epidemiology and risk factors asso- ciated with hip replacement surgery显示文摘 | Vander Cruyssen B Mu oz-Gomariz E Font P | 2010 | Rheumatology (Oxford)2010，49，1： | 1 |
| 10 | The outcome of poskrolater al fusion in highly sekeiod patients with diseogenie low back pain显示文摘 | PARKER L M MU NELL S E BODEN S D | 1996 | Spine1996，21，16： | 1 |
| 11 | Effects of high voltage electric pulses on protein based food constituents and structures 显示文摘 | Barsotti L Dumay E Mu T H | 2002 | Trends in Food Science and Technology2002，12，34： | 1 |
| 12 | Cardiac dysfunction after left permanent cerebral focal ischemia:the brain and heart connection显示文摘 | Min J Farooq MU Greenberg E | 2009 | Stroke2009，40，7： | 1 |
| 13 | Single-carrier frequency-domain equalization based on frequency-domain oversampling显示文摘 | Zhang Xiao-hui Chen E and Mu Xiao-min | 2012 | IEEE Communications Letters2012，16，1： | 1 |
| 14 | Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine显示文摘 | Ebba N Frode E Per MU | 2000 | Clin Chem2000，46，： | 1 |
| 15 | Choice of lens and dioptric power in pediatric pseudophakia显示文摘 | Dahan E Drusedau MU | 1997 | Cataract Refract Surg1997，23，1： | 1 |
| 16 | Severe cerebral white matter involvement in a case of dentatorubropallidoluysian atrophy studied at autopsy显示文摘 | Mu(n)oz E Campdelacreu J Ferrer I | 2004 | Arch Neurol2004，61，6： | 1 |
| 17 | The con- stituents of essential oil and in vitro antimicrobial activity of Micromeria cilicica from Turkey 显示文摘 | DURU M E OZTURK MU A CEYLAN O | 2004 | J Ethnopharmacol2004，94，1： | 1 |
| 18 | Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis显示文摘 | Muoz-Fernández S de Miguel E Cobo-Ibáez T | 2009 | Arthritis Rheum2009，60，： | 1 |
| 19 | Vancouver type B2 fractures:best choice of treatment显示文摘 | Guerra-Farfán E Carrera L Mu(n)eton D | 2013 | Eur Orthop Traumatol2013，4，： | 1 |
| 20 | On the time polynomial decay in elastic solids with voids显示文摘 | Mu(n)oz Rivera J E Quintanilla R | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员